Olema Pharmaceuticals, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Filed March 9, 2023. Olema is a clinical-stage biotechnology company with no approved products and no product sales; its lead candidate is OP-1250, an oral estrogen-receptor antagonist and degrader being studied for ER-positive breast cancer.
Financial and operating results
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $82.3 million | $51.1 million |
| General and administrative expense | $24.7 million | $20.4 million |
| Total operating expenses | $107.0 million | $71.5 million |
| Net loss | $104.8 million | $71.1 million |
| Net loss per share, basic and diluted | $2.62 | $1.80 |
| Net cash used in operating activities | $82.1 million | $50.7 million |
| Cash, cash equivalents and marketable securities at year-end | $204.4 million | $287.3 million |
Losses widened as R&D investment rose to advance OP-1250 and other research, including an $8.0 million upfront Aurigene license payment; higher staffing and stock-based compensation also contributed. Higher interest income partly offset operating losses. Profit margins are not meaningful because the company has no product revenue.
Year-end current assets were $208.9 million and current liabilities were $16.5 million; total liabilities were $18.1 million. The company reported no debt outstanding. Marketable securities were $180.7 million, including $1.8 million of unrealized losses attributed to market conditions rather than credit concerns. The auditor issued an unqualified opinion on the financial statements. Management said liquidity was expected to fund planned operations into 2025, but also stated that additional capital will be required and that losses and negative operating cash flows raise substantial doubt about long-term continuation as a going concern.
Clinical progress and changes versus prior year
- OP-1250 monotherapy advanced from Phase 1 dose expansion into Phase 2; 120 mg once daily was selected as the recommended Phase 2 dose. The first two Phase 2 cohorts were fully enrolled in Q4 2022.
- In preliminary Phase 1b data, six partial responses were reported among 57 efficacy-evaluable patients (four confirmed, two unconfirmed); 41% had reductions in target lesions. The reported clinical benefit rate at 120 mg was 39% (7 of 18 eligible patients). These are interim results, not pivotal evidence.
- Combination studies with palbociclib, ribociclib and alpelisib were initiated. Preliminary palbociclib results in 12 patients showed no observed drug-drug interaction; neutropenia was reported, consistent with the known palbociclib profile.
- The FDA granted OP-1250 Fast Track designation in July 2022 for a specified population with ER+/HER2- metastatic breast cancer. This designation does not guarantee approval or a faster development outcome.
Outlook, material events and risks
- At the time of filing, management anticipated monotherapy Phase 2 data in the second half of 2023 and planned to discuss a pivotal Phase 3 trial with regulators, with a potential start in the second half of 2023 subject to FDA and EMA feedback. A combination Phase 3 trial was contemplated for 2024, conditional on study results. These are forward-looking plans, not reported outcomes.
- On March 9, 2023, the company announced a restructuring to prioritize late-stage OP-1250 development, reducing its workforce by approximately 25%. It estimated a one-time charge of about $2.8 million, mostly cash costs expected in Q1 2023.
- Also on March 9, 2023, Olema entered an at-the-market offering agreement allowing sales of up to $100 million of common stock. Sales are optional; any issuance could dilute shareholders.
- Aurigene agreement terms include the $8.0 million upfront payment, up to $60 million in development and regulatory milestones, up to $370 million in commercial milestones, and tiered royalties. No milestone expense was recorded at year-end because achievement was not considered probable.
- Key risks include dependence on OP-1250, uncertain clinical and regulatory outcomes, continuing cash burn and financing needs, competition, trial enrollment delays, adverse effects, and reliance on contract manufacturers and CROs. Olema reported no material pending legal proceedings and no long-term OP-1250 supply agreements or contracted redundant supply at year-end.
Most important facts for investors to verify
- Whether subsequent clinical data support the preliminary response and tolerability findings, and whether regulators agree with the proposed Phase 3 design and timing.
- Actual cash burn, liquidity runway and any equity sales under the $100 million ATM program, including resulting dilution.
- Implementation costs and savings from the 25% workforce reduction, and whether the portfolio focus changes development timelines.
- Manufacturing capacity and supply redundancy for OP-1250, and progress toward pivotal-trial and potential commercial supply.
- Terms and potential financial impact of Aurigene milestones and royalties, alongside the company’s long-term funding and going-concern disclosures.